3//SEC Filing
Ogden CAP Associates, LLC 3
Accession 0001882178-21-000021
CIK 0001455365other
Filed
Oct 6, 8:00 PM ET
Accepted
Oct 7, 8:26 PM ET
Size
12.1 KB
Accession
0001882178-21-000021
Insider Transaction Report
Form 3
Ogden CAP Associates, LLC
10% Owner
Holdings
Series A Convertible Preferred Stock
→ Common Stock (407,916 underlying)Series A-1 Convertible Preferred Stock
→ Common Stock (103,055 underlying)Series A-2 Convertible Preferred Stock
→ Common Stock (272,756 underlying)Series B Convertible Preferred Stock
→ Common Stock (1,263,575 underlying)Series B-1 Convertible Preferred Stock
→ Common Stock (135,679 underlying)Warrant (Right to Buy)
Exercise: $0.03From: 2016-03-15Exp: 2023-03-15→ Common Stock (27,471 underlying)
Footnotes (6)
- [F1]The Series A Convertible Preferred Stock is convertible into shares of common stock on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-3.2345 reverse stock split effected on October 1, 2021, pursuant to which each share of Series A Convertible Preferred Stock was adjusted to become convertible into 0.309166795 shares of common stock.
- [F2]The Series A-1 Convertible Preferred Stock is convertible into shares of common stock on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-3.2345 reverse stock split effected on October 1, 2021, pursuant to which each share of Series A-1 Convertible Preferred Stock was adjusted to become convertible into 0.309166795 shares of common stock.
- [F3]The Series A-2 Convertible Preferred Stock is convertible into shares of common stock on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-3.2345 reverse stock split effected on October 1, 2021, pursuant to which each share of Series A-2 Convertible Preferred Stock was adjusted to become convertible into 0.309166795 shares of common stock.
- [F4]The Series B Convertible Preferred Stock is convertible into shares of common stock on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-3.2345 reverse stock split effected on October 1, 2021, pursuant to which each share of Series B Convertible Preferred Stock was adjusted to become convertible into 0.309166795 shares of common stock.
- [F5]The Series B-1 Convertible Preferred Stock is convertible into shares of common stock on a one-for-one basis and has no expiration date. The number of underlying shares of common stock reported in Column 3 reflects a 1-for-3.2345 reverse stock split effected on October 1, 2021, pursuant to which each share of Series B-1 Convertible Preferred Stock was adjusted to become convertible into 0.309166795 shares of common stock.
- [F6]The warrant expries on the earliest of (i) March 15, 2023, (ii) upon a liquidation, dissolution or winding up of the Company, (iii) the closing of a Sale Transaction (as defined in the warrant), (iv) upon the closing of the issuer's Initial Public Offering ("IPO") or (v) upon repayment of a promissory note issued in connection with the warrant.
Documents
Issuer
COGNITION THERAPEUTICS INC
CIK 0001455365
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001885867
Filing Metadata
- Form type
- 3
- Filed
- Oct 6, 8:00 PM ET
- Accepted
- Oct 7, 8:26 PM ET
- Size
- 12.1 KB